Cipla - Margin Improvement - A Healthy Sign.

Date: August 8, 2011
Pages: 6
Price:
US$ 140.00
Publisher: MP Advisors
Report type: Company Report
Delivery: E-mail Delivery (PDF), Online Subscription, E-mail Delivery (Word)
ID: CFCE4A19C3DEN
Leaflet:

Download PDF Leaflet

Cipla - Margin Improvement - A Healthy Sign.
We reiterate our Market Perform rating on CIPLA after its Q1 FY12 result that was lower than our sales expectations, but higher than our earnings estimate owing to the sharp improvement in gross margin. The improvement in gross margin (up by 330 bps, Y-o-Y) is largely due to the commissioning of the Indore facility operating at a breakeven level this quarter. The muted sales growth at 7.5% was partly due to the decline in sales from ARV.

Although we continue believe that CIPLA’s structural issues are yet not over, we expect drastic upside in the near term owing to (1) $100m of EBITDA from supply of API of generic Zyprexa to Teva under 180-day exclusivity and (2) improvement in margin as contribution from Indore facility increases. For the longer term, CIPLA’s traditional business model with back ended focus in regulated markets remains a major bottleneck.

We keep our estimates unchanged and reiterate our Positive Investment Alert on CIPLA. Our target price remains at Rs.306.
COMPANIES MENTIONED

Cipla
Skip to top


Ask Your Question

Cipla - Margin Improvement - A Healthy Sign.
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: